{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:37:20Z","timestamp":1787315840416,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2023-00265860"],"award-info":[{"award-number":["RS-2023-00265860"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Food and Chemical Toxicology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.fct.2023.113946","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T02:19:17Z","timestamp":1689214757000},"page":"113946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Safety concerns regarding impurities in L-Tryptophan associated with eosinophilia myalgia syndrome"],"prefix":"10.1016","volume":"179","author":[{"given":"Soo Min","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Kyung","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Uk","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4052-8745","authenticated-orcid":false,"given":"Woo-Chan","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.fct.2023.113946_bib1","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002040050169","article-title":"Accumulation of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in blood and organs of the Lewis rats","volume":"69","author":"Adachi","year":"1995","journal-title":"Arch. Toxicol."},{"issue":"8","key":"10.1016\/j.fct.2023.113946_bib2","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s002040050102","article-title":"Identification of four metabolites of 3-(phenylamino) alanine, a constituent in l-tryptophan products implicated in eosinophiliamyalgia syndrome, in rats","volume":"68","author":"Adachi","year":"1994","journal-title":"Arch. Toxicol."},{"issue":"4","key":"10.1016\/j.fct.2023.113946_bib3","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/BF01974348","article-title":"Metabolism and distribution in the rat of peak E substance, a constituent inl-tryptophan product implicated in eosinophilia-myalgia syndrome","volume":"67","author":"Adachi","year":"1993","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.fct.2023.113946_bib4","series-title":"Encyclopedia of Toxicology","first-page":"419","article-title":"Eosinophilia-myalgia syndrome","author":"Allen","year":"2014"},{"issue":"11","key":"10.1016\/j.fct.2023.113946_bib5","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1002\/art.30514","article-title":"Post\u2010epidemic eosinophilia\u2013myalgia syndrome associated with L\u2010tryptophan","volume":"63","author":"Allen","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.fct.2023.113946_bib6","series-title":"Meyler's Side Effects of Drugs: the International Encyclopedia of Adverse Drug Reactions and Interactions","author":"Aronson","year":"2015"},{"issue":"6","key":"10.1016\/j.fct.2023.113946_bib7","first-page":"796","article-title":"Eosinophilia-myalgia syndrome induced by excessive L-tryptophan intake from cashew nuts","volume":"9","author":"Bare\u0161i\u0107","year":"2014","journal-title":"Cent. Eur. J. Med."},{"issue":"6","key":"10.1016\/j.fct.2023.113946_bib8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199008093230601","article-title":"An investigation of the cause of the eosinophilia\u2013myalgia syndrome associated with tryptophan use","volume":"323","author":"Belongia","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.fct.2023.113946_bib9","series-title":"Paper Presented at the Seminars in Arthritis and Rheumatism","article-title":"Eosinophilia myalgia syndrome","author":"Blackburn","year":"1997"},{"issue":"2","key":"10.1016\/j.fct.2023.113946_bib10","first-page":"1029","article-title":"A decomposition product of a contaminant implicated in L-tryptophan eosinophilia myalgia syndrome affects spinal cord neuronal cell death and survival through stereospecific, maturation and partly interleukin-1-dependent mechanisms","volume":"266","author":"Brenneman","year":"1993","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"5","key":"10.1016\/j.fct.2023.113946_bib12","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1172\/JCI114902","article-title":"L-tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat","volume":"86","author":"Crofford","year":"1990","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.fct.2023.113946_bib13","first-page":"354","article-title":"MAST-CELL and eosinophil infiltration in intestinal-mucosa of lewis rats treated with l-tryptophan implicated in human eosinophilia-myalgia-syndrome","volume":"4","author":"DeSchryver-Kecskemeti","year":"1991","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/j.fct.2023.113946_bib14","article-title":"Safety and efficacy of l-tryptophan produced with Escherichia coli CGMCC 11674 for all animal species","volume":"17","year":"2019","journal-title":"EFSA J."},{"issue":"12","key":"10.1016\/j.fct.2023.113946_bib15","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.44.12.2390","article-title":"1, 1'\u2010Ethylidenebis\u2010[tryptophan] induces pathologic alterations in muscle similar to those observed in the eosinophilia\u2010myalgia syndrome","volume":"44","author":"Emslie-Smith","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.fct.2023.113946_bib16","series-title":"Information Paper on L-Tryptophan and 5-Hydroxy-Ltryptophan","author":"FDA","year":"2001"},{"key":"10.1016\/j.fct.2023.113946_bib17","author":"FDA"},{"key":"10.1016\/j.fct.2023.113946_bib18","author":"FDA"},{"key":"10.1016\/j.fct.2023.113946_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/jpn.13515","article-title":"Tryptophan in poultry nutrition: impacts and mechanisms of action","author":"Fouad","year":"2021","journal-title":"J. Anim. Physiol. Anim. Nutr."},{"issue":"6","key":"10.1016\/j.fct.2023.113946_bib20","first-page":"747","article-title":"[Acute respiratory failure as a manifestation of eosinophilia-myalgia syndrome associated with L-tryptophan intake]","volume":"33","author":"Grangeia Tde","year":"2007","journal-title":"J. Bras. Pneumol."},{"key":"10.1016\/j.fct.2023.113946_bib21","series-title":"Pulmonary Vascular Disease","first-page":"237","article-title":"Chapter 15 - pulmonary vasculitis","author":"Groskreutz","year":"2006"},{"key":"10.1016\/j.fct.2023.113946_bib22","series-title":"PDR for Nutritional Supplements","author":"Hendler","year":"2008"},{"issue":"1","key":"10.1016\/j.fct.2023.113946_bib23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/BF00230724","article-title":"Contaminants in L-tryptophan associated with eosinophilia myalgia syndrome","volume":"25","author":"Hill","year":"1993","journal-title":"Arch. Environ. Contam. Toxicol."},{"issue":"3","key":"10.1016\/j.fct.2023.113946_bib24","first-page":"1544","article-title":"Roles of tryptophan in monogastric nutrition: a review","volume":"4","author":"Iwuji","year":"2014","journal-title":"Adv. Agric. Sci. Eng. Res."},{"key":"10.1016\/j.fct.2023.113946_bib25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.toxrep.2020.01.013","article-title":"Genotoxicity and acute toxicity evaluation of the three amino acid additives with Corynebacterium glutamicum biomass","volume":"7","author":"Kang","year":"2020","journal-title":"Toxicol Rep"},{"key":"10.1016\/j.fct.2023.113946_bib26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/oxfordjournals.epirev.a036085","article-title":"Eosinophilia-myalgia syndrome: coming to grips with a new illness","volume":"14","author":"Kilbourne","year":"1992","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.fct.2023.113946_bib27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.toxlet.2017.10.012","article-title":"Structure determination of disease associated peak aaa from l-tryptophan implicated in the eosinophilia-myalgia syndrome","volume":"282","author":"Klarskov","year":"2018","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.fct.2023.113946_bib28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.toxlet.2018.05.027","article-title":"Peak AAA fatty acid homolog contaminants present in the dietary supplement l-Tryptophan associated with the onset of eosinophilia-myalgia syndrome","volume":"294","author":"Klarskov","year":"2018","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.fct.2023.113946_bib29","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.toxrep.2022.05.005","article-title":"Safety evaluation of dried L-tryptophan fermentation product in Sprague-Dawley rats","volume":"9","author":"Ko","year":"2022","journal-title":"Toxicol Rep"},{"issue":"5","key":"10.1016\/j.fct.2023.113946_bib30","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00726-010-0752-7","article-title":"Tryptophan metabolism, from nutrition to potential therapeutic applications","volume":"41","author":"Le Floc'h","year":"2011","journal-title":"Amino Acids"},{"issue":"1\u20132","key":"10.1016\/j.fct.2023.113946_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.livsci.2007.07.002","article-title":"Biological roles of tryptophan and its metabolism: potential implications for pig feeding","volume":"112","author":"Le Floc'h","year":"2007","journal-title":"Livest. Sci."},{"issue":"3","key":"10.1016\/j.fct.2023.113946_bib32","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1172\/JCI116300","article-title":"Pathological and immunological effects of ingesting L-tryptophan and 1,1'-ethylidenebis (L-tryptophan) in Lewis rats","volume":"91","author":"Love","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.fct.2023.113946_bib33","author":"Mary Kugler"},{"issue":"4988","key":"10.1016\/j.fct.2023.113946_bib34","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1126\/science.2270484","article-title":"Characterization of\" peak E,\" a novel amino acid associated with eosinophilia-myalgia syndrome","volume":"250","author":"Mayeno","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.fct.2023.113946_bib35","first-page":"383","article-title":"Learning the hard way: L-tryptophan, the FDA, and the regulation of amino acids","volume":"3","author":"McGowan","year":"1993","journal-title":"Cornell JL & Pub. Pol'y"},{"key":"10.1016\/j.fct.2023.113946_bib36","series-title":"Tryptophan, Serotonin, and Melatonin","first-page":"481","article-title":"Synthesis and formation of an EMS correlated contaminant in biotechnologically manufactured L-tryptophan","author":"M\u00fcller","year":"1999"},{"key":"10.1016\/j.fct.2023.113946_bib37","series-title":"Tryptophan, Serotonin, and Melatonin","first-page":"453","article-title":"Structural characterization of case-associated contaminants peak C and FF in L-tryptophan implicated in eosinophilia-myalgia syndrome","author":"Naylor","year":"1999"},{"key":"10.1016\/j.fct.2023.113946_bib38","unstructured":"NORD. Eosinophilia-Myalgia Syndrome. Retrieved from Eosinophilia-Myalgia Syndrome - NORD (National Organization for Rare Disorders) (rarediseases.org)."},{"key":"10.1016\/j.fct.2023.113946_bib39","series-title":"Nutrient Requirements of Poultry Ninth Revised","year":"1994"},{"key":"10.1016\/j.fct.2023.113946_bib40","series-title":"Nutrient Requirements of Swine","year":"2012"},{"issue":"4","key":"10.1016\/j.fct.2023.113946_bib41","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/BF01974349","article-title":"Accumulation of 1-methyl-tetrahydro-\u0392-carboline-3-carboxylic acid in blood and organs of rat. A possible causative substance of eosinophilia-myalgia syndrome associated with ingestion ofl-tryptophan","volume":"67","author":"Ogawa","year":"1993","journal-title":"Arch. Toxicol."},{"issue":"21","key":"10.1016\/j.fct.2023.113946_bib42","doi-asserted-by":"crossref","first-page":"8647","DOI":"10.1073\/pnas.87.21.8647","article-title":"Hypodense eosinophils and interleukin 5 activity in the blood of patients with the eosinophilia-myalgia syndrome","volume":"87","author":"Owen","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.fct.2023.113946_bib43","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/15376520500195616","article-title":"Does 5-hydroxytryptophan cause acute and chronic toxic perturbations in rats?","volume":"16","author":"Preuss","year":"2006","journal-title":"Toxicol. Mech. Methods"},{"issue":"12","key":"10.1016\/j.fct.2023.113946_bib44","doi-asserted-by":"crossref","first-page":"2635S","DOI":"10.3945\/jn.116.234591","article-title":"The safety and regulatory process for amino acids in Europe and the United States","volume":"146","author":"Roberts","year":"2016","journal-title":"J. Nutr."},{"issue":"4","key":"10.1016\/j.fct.2023.113946_bib45","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/jat.3562","article-title":"Thirteen week toxicity study of dietary l\u2010tryptophan in rats with a recovery period of 5 weeks","volume":"38","author":"Shibui","year":"2018","journal-title":"J. Appl. Toxicol."},{"issue":"1\u20132","key":"10.1016\/j.fct.2023.113946_bib46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0300-483X(94)90058-2","article-title":"Effect of 3-phenylamino-L-alanine on tryptophan binding to rat hepatic nuclear envelopes","volume":"86","author":"Sidransky","year":"1994","journal-title":"Toxicology"},{"issue":"4","key":"10.1016\/j.fct.2023.113946_bib47","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1172\/JCI117125","article-title":"A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan)","volume":"93","author":"Silver","year":"1994","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.fct.2023.113946_bib48","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00217-002-0646-3","article-title":"Contamination of commercially available L-tryptophan by related substances","volume":"216","author":"Simat","year":"2003","journal-title":"Eur. Food Res. Technol."},{"issue":"10","key":"10.1016\/j.fct.2023.113946_bib49","first-page":"1711","article-title":"Eosinophilia-myalgia syndrome: mortality data from the US national surveillance system","volume":"20","author":"Swygert","year":"1993","journal-title":"J. Rheumatol."},{"issue":"7","key":"10.1016\/j.fct.2023.113946_bib50","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1271\/bbb.58.1318","article-title":"Formation of a 3-(phenylamino) alanine contaminant in EMS-associated L-tryptophan","volume":"58","author":"Toyoda","year":"1994","journal-title":"Biosc. Biotech. Biochem."},{"issue":"1","key":"10.1016\/j.fct.2023.113946_bib51","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1038\/jid.1993.31","article-title":"L-tryptophan and the eosinophilia-myalgia syndrome: current understanding of the etiology and pathogenesis","volume":"100","author":"Varga","year":"1993","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.fct.2023.113946_bib52","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-4274(98)00223-9","article-title":"On-line HPLC-tandem mass spectrometry structural characterization of case-associated contaminants of L-tryptophan implicated with the onset of eosinophilia myalgia syndrome","volume":"99","author":"Williamson","year":"1998","journal-title":"Toxicol. Lett."}],"container-title":["Food and Chemical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278691523003484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278691523003484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T15:11:43Z","timestamp":1736349103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278691523003484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":51,"alternative-id":["S0278691523003484"],"URL":"https:\/\/doi.org\/10.1016\/j.fct.2023.113946","relation":{},"ISSN":["0278-6915"],"issn-type":[{"value":"0278-6915","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety concerns regarding impurities in L-Tryptophan associated with eosinophilia myalgia syndrome","name":"articletitle","label":"Article Title"},{"value":"Food and Chemical Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fct.2023.113946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113946"}}